Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The treatment of epidermal growth factor receptor (EGFR)-mutated lung cancer cases has shown remarkable development in the past two decades. However, there have been limited studies comparing the prognostic effects of EGFR-tyrosine kinase inhibitor (TKI) and other treatment modalities. Therefore, we compared the survival outcomes of patients treated with EGFR-TKIs versus those treated with other treatment modalities. Methods: Patient data were collected from the Korean National Health Insurance Database, National Health Insurance Service- National Sample Cohort 2002 to 2015, which was released by the Korean National Health Insurance Service in 2015. The lung cancer group included patients (n = 2,003) initially diagnosed with lung cancer between January 2010 and December 2013. The main outcome was all-cause mortality. A Cox proportional hazard regression analysis was used to calculate the relative risk of mortality. Results: Among the newly diagnosed lung cancer cases, 1,004 (50.1%) were included in the analysis. A 15.1-month median survival benefit was observed in the EGFR-TKI group than that of the multimodality therapy group. The risk of mortality was as follows: EGFR-TKI treatment group (n = 142; hazard ratio [HR], 5.29; 95% confidence interval [CI], 3.57 to 7.86) and multimodality therapy group (n = 326; HR, 7.42; 95% CI, 5.19 to 10.63) compared to surgery only (n = 275). Conclusions: Patients with advanced lung cancer harbouring EGFR mutations treated with EGFR-TKIs showed better median survival and lower risk of mortality than those in the multimodality therapy group. In the case of EGFR-mutated advanced lung cancer, there is room for downstaging in the TNM classification.
Abstract
Background/Aims: The treatment of epidermal growth factor receptor (EGFR)-mutated lung cancer cases has shown remarkable development in the past two decades. However, there have been limited studies comparing the prognostic effects of EGFR-tyrosine kinase inhibitor (TKI) and other treatment modalities. Therefore, we compared the survival outcomes of patients treated with EGFR-TKIs versus those treated with other treatment modalities. Methods: Patient data were collected from the Korean National Health Insurance Database, National Health Insurance Service- National Sample Cohort 2002 to 2015, which was released by the Korean National Health Insurance Service in 2015. The lung cancer group included patients (n = 2,003) initially diagnosed with lung cancer between January 2010 and December 2013. The main outcome was all-cause mortality. A Cox proportional hazard regression analysis was used to calculate the relative risk of mortality. Results: Among the newly diagnosed lung cancer cases, 1,004 (50.1%) were included in the analysis. A 15.1-month median survival benefit was observed in the EGFR-TKI group than that of the multimodality therapy group. The risk of mortality was as follows: EGFR-TKI treatment group (n = 142; hazard ratio [HR], 5.29; 95% confidence interval [CI], 3.57 to 7.86) and multimodality therapy group (n = 326; HR, 7.42; 95% CI, 5.19 to 10.63) compared to surgery only (n = 275). Conclusions: Patients with advanced lung cancer harbouring EGFR mutations treated with EGFR-TKIs showed better median survival and lower risk of mortality than those in the multimodality therapy group. In the case of EGFR-mutated advanced lung cancer, there is room for downstaging in the TNM classification.
참고문헌 (25)
- Rosell R, "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial", Lancet Oncol, 13, pp.239~246 (2012)
- Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
- Han JY, "First-SIGNAL : first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung", J Clin Oncol, 30, pp.1122~1128 (2012)
- Sequist LV, "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations", J Clin Oncol, 31, pp.3327~3334 (2013)
- Janne PA, "AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer", N Engl J Med, 372, pp.1689~1699 (2015)
- Mok TS, "Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer", N Engl J Med, 376, pp.629~640 (2017)
- Reungwetwattana T, "CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer", J Clin Oncol, 36, pp.3290~3297 (2018)
- Lim W, "The 8th lung cancer TNM classification and clinical staging system : review of the changes and clinical implications", Quant Imaging Med Surg, 8, pp.709~718 (2018)
- "Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer: adopted on May 16, 1997by the American Society of Clinical Oncology", J Clin Oncol, 15, pp.2996~3018 (1997)
- Miller JD, "Staging : the key to rational management of lung cancer", Ann Thorac Surg, 53, pp.170~178 (1992)
- Rami-Porta R, "The IASLC Lung Cancer Staging Project : proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer", J Thorac Oncol, 10, pp.990~1003 (2015)
- Asamura H, "The International Association for the Study of Lung Cancer Lung Cancer Staging Project : proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer", J Thorac Oncol, 10, pp.1675~1684 (2015)
- 최원일, "Higher Age Puts Lung Cancer Patients at Risk for Not Receiving Anti-cancer Treatment", Cancer Research and Treatment, 51(3), pp.1241~1248 (2019), 대한암학회
- Choi WI, "Association between EGFR mutation and ageing, history of pneumonia and gastroesophageal reflux disease among patients with advanced lung cancer", Eur J Cancer, 122, pp.101~108 (2019)
- 김호철, "Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer Registry", Tuberculosis and Respiratory Diseases, 82(2), pp.118~125 (2019), 대한결핵및호흡기학회[DOI]
- Mitsudomi T, "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405) : an open label, randomised phase 3 trial", Lancet Oncol, 11, pp.121~128 (2010)
- Park K, "Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer(LUX-Lung 7) : a phase 2B, open-label, randomized controlled trial", Lancet Oncol, 17, pp.577~589 (2016)
- Wu YL, "Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations(LUX-Lung 6) : an open-label, randomised phase 3 trial", Lancet Oncol, 15, pp.213~222 (2014)
- Goldstraw P, "The IASLC Lung Cancer Staging Project : proposals for revision of the TNM stage groupings in the forthcoming(eighth)edition of the TNM classification for lung cancer", J Thorac Oncol, 11, pp.39~51 (2016)
- Ramalingam SS, "Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC", N Engl J Med, 382, pp.41~50 (2020)
- Soria JC, "Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer", N Engl J Med, 378, pp.113~125 (2018)
- Wu YL, "Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer(ARCHER 1050) : a randomised, open-label, phase 3 trial", Lancet Oncol, 18, pp.1454~1466 (2017)
- Cha YK, "Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy", Clin Lung Cancer, 16, pp.228~236 (2015)
- Lee Y, "Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated nonsmall cell lung cancer", Thorac Cancer, 9, pp.1104~1110 (2018)
- Lim YJ, "Superior treatment response and in-field tumor control in epidermal growth factor receptor-mutant genotype of stage III nonsquamous non-small cell lung cancer undergoing definitive concurrent chemoradiotherapy", Clin Lung Cancer, 18, pp.e169~e178 (2017)